Instrumento Inactivo

Otros idiomas Neurotrope Inc Other OTC

Acciones

US64129T2078

Precio de cierre Other OTC Otros sitios de cotización
- ^USD	-

2020	Neurotrope, Inc. informa de los resultados del tercer trimestre finalizado el 30 de septiembre de 2020	CI
2020	Neurotrope, Inc. informa de los resultados del segundo trimestre finalizado el 30 de junio de 2020	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Neurotrope, Inc. completed the spin-off of Neurotrope Bioscience, Inc.	02/12/20
Metuchen Pharmaceuticals LLC completed the acquisition of Neurotrope, Inc. from Intracoastal Capital LLC and others in a reverse merger transaction.	01/12/20
NEUROTROPE, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	25/11/20
NEUROTROPE, INC. : Other Events (form 8-K)	24/11/20
NEUROTROPE, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	20/11/20
NEUROTROPE : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	09/11/20
Neurotrope, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	09/11/20
Neurotrope, Inc Announces Dosing of the First Patient in Its Ongoing, Long-Term Phase 2 Study of Bryostatin-1 for the Treatment of Alzheimer's Disease	06/10/20
NEUROTROPE, INC. : Other Events (form 8-K)	30/09/20
NEUROTROPE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	30/09/20
NEUROTROPE : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	10/08/20
Neurotrope, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	10/08/20
NEUROTROPE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	29/07/20
NEUROTROPE, INC. : Other Events (form 8-K)	24/07/20
NEUROTROPE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	24/07/20
Neurotrope : Announces Strategic Partnership with BryoLogyx for Supply of Synthetic Bryostatin-1 and Continuation of the National Cancer Institute Trial for Childhood Leukemia	15/06/20
NEUROTROPE : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	12/06/20
Neurotrope, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	12/06/20
Bryologyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1	10/06/20
NEUROTROPE, INC. : Regulation FD Disclosure, Other Events (form 8-K)	28/05/20

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Neurotrope Inc Other OTC

Acciones

US64129T2078

Otros idiomas

Filtros